Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 10/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15574354 | 0.88 | ALDH1A1 (0.49) | LPLLIPGIRAK4ALDH1A1IDO1 | |
| SCHEMBL28483833 | 0.84 | LPL (0.39) | LPLLIPGIRAK4IDO1TDO2 | |
| SCHEMBL30016416 | 0.84 | FABP6 (0.42) | LPLLIPGIRAK4ALDH1A1SNCA | |
| SCHEMBL3132769 | 0.84 | FABP6 (0.42) | LPLLIPGIRAK4ALDH1A1SNCA | |
| SCHEMBL16655694 | 0.84 | LPL (0.39) | LPLLIPGIRAK4IDO1TDO2 | |
| SCHEMBL13201515 | 0.81 | DDAH1 (0.46) | LPLLIPGIRAK4SNCAPRMT5 | |
| SCHEMBL31037319 | 0.80 | KDM4E (0.48) | LPLLIPGIRAK4ALDH1A1IDO1 | |
| SCHEMBL14658441 | 0.80 | NPSR1 (0.45) | LPLLIPGIRAK4ALDH1A1IDO1 | |
| SCHEMBL3263196 | 0.80 | KDM4E (0.48) | LPLLIPGIRAK4ALDH1A1IDO1 | |
| SCHEMBL16062202 | 0.79 | LPL (0.51) | LPLLIPGALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203034-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203034-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210198257-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2021-07-01 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-10975075-B2 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | MERCK PATENT GMBH (DE) | 2021-04-13 | — | — | US | disclosed |
| EP-3560924-B1 | IMIDAZOLONYL QUINOLINES AND THEIR USE AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2021-03-31 | — | — | EP | disclosed |
| US-20200325137-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2020-10-15 | — | — | US | disclosed |
| US-10745399-B2 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | MERCK PATENT GMBH (DE) | 2020-08-18 | — | — | US | disclosed |
| EP-3560924-A1 | IMIDAZOLONYL QUINOLINES AND THEIR USE AS ATM KINASE INHIBITORS | Merck Patent GmbH (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-10457677-B2 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | MERCK PATENT GMBH (DE) | 2019-10-29 | — | — | US | disclosed |
| US-20190211013-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2019-07-11 | — | — | US | disclosed |
| EP-3277681-B1 | IMIDAZOLONYLQUINOLINES AND THEIR USE AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2019-05-08 | — | — | EP | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20180072715-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203034-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | LPL 2838/4885LIPG 2601/4885IRAK4 275/4885 |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | LPL 4723/4885LIPG 4081/4885IRAK4 1632/4885 |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | LPL 4723/4885LIPG 4081/4885IRAK4 1632/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | LPL 4723/4885LIPG 4081/4885IRAK4 1632/4885 |
| US-20190211013-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | LPL 2838/4885LIPG 2601/4885IRAK4 275/4885 |
| US-10457677-B2 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | ATM, CHEK2, CHEK1 | LPL 2955/4885LIPG 2883/4885IRAK4 371/4885 |
| US-10975075-B2 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | ATM, CHEK2, CHEK1 | LPL 3015/4885LIPG 2603/4885IRAK4 132/4885 |
| US-20210198257-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | LPL 2838/4885LIPG 2601/4885IRAK4 275/4885 |
| US-10745399-B2 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | ATM, CHEK2, CHEK1 | LPL 3338/4885LIPG 2603/4885IRAK4 122/4885 |
| US-20200325137-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | LPL 2838/4885LIPG 2601/4885IRAK4 275/4885 |
| US-20180072715-A1 | IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS | ATM, CHEK2, CHEK1 | LPL 2955/4885LIPG 2883/4885IRAK4 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.